Skip to content

Effect and mechanism of BTX-A on cough hypersensitivity through TRP family—a prospective, randomized, controlled, double-blind study of BTX-A in the treatment of refractory cough

Effect and mechanism of BTX-A on cough hypersensitivity through TRP family

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031824
Enrollment
Unknown
Registered
2020-04-11
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory chronic cough

Interventions

control group:Inject 0.1mL normal saline into the unilateral arytenoid muscle by OT syringe
experimental group:Inject BTX-A 1.25U into the unilateral arytenoid muscle by OT syringe

Sponsors

Tongji Hospital Affiliated to Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 - 60 years are not limited to men and women; 2. Patients with cough as the main symptom, cough time more than 8 weeks, and no obvious abnormality on chest X-ray or CT; 3. Patients with chronic cough whose cause is still unclear after comprehensive examination according to the chronic cough diagnosis procedure of Chinese cough diagnosis and treatment guidelines (2015) or whose treatment for known cause is still unresponsive; 4. Patients with cough visual analogue score (VAS) >= 50 mm; 5. Patients willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with asthma, urticaria or allergic reaction induced by BTX-A; 2. Patients with severe heart failure and coronary artery bypass grafting (CABG) in perioperative period; 3. Patients with liver and kidney dysfunction; 4. Pregnant women and lactating women; 5. Patients with myasthenia gravis and multiple sclerosis; 6. Patients with ptosis; 7. Patients with dysphagia and cough caused by any etiology; 8. Smoking patients or patients who have quit smoking for less than 1 year; 9. Patients with upper respiratory tract infection within 4 weeks; 10. Patients who need ACEI drugs for a long time; 11. Patients with moderate or more obstructive or restrictive or mixed pulmonary ventilation dysfunction.

Design outcomes

Primary

MeasureTime frame
Cough symptom score;Leicester Cough Questionnaire score;Visual Analogue Score;

Countries

China

Contacts

Public ContactXu Xianghuai

Tongji Hospital Affiliated to Tongji University

05849@tongji.edu.cn+86 13764459488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026